Evidence map›Paper›PMID 40434309›Full record

Trial reportClinical and translational gastroenterology2025

Effects of Ricinoleic Acid (Castor Oil) on Gut Permeability in Healthy Participants: Provocative Test for Treatments Aimed at Restoring Barrier Function.

David Yi Yang, Camille Lupianez-Merly, Kara J Jencks, Saam Dilmaghani, Irene Busciglio, Deborah Eckert, Michael Ryks, Roy Dyer, Brady A Vizenor, Yuxi Zhao and 4 more

Abstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Clinical and translational gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

David Yi YangClinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Camille Lupianez-MerlyClinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Kara J JencksClinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Saam DilmaghaniClinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Irene BusciglioClinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Deborah EckertClinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Michael RyksClinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.
Roy DyerImmunochemical Core Laboratory, Mayo Clinic, Rochester, Minnesota, USA.
Brady A VizenorImmunochemical Core Laboratory, Mayo Clinic, Rochester, Minnesota, USA.
Yuxi ZhaoPfizer Research and Development, Cambridge, Massachusetts, USA .
Anna SaponePfizer Research and Development, Cambridge, Massachusetts, USA .
Michelle G RooksPfizer Research and Development, Cambridge, Massachusetts, USA .
Jeremy D GalePfizer Research and Development, Cambridge, Massachusetts, USA .
Michael CamilleriClinical Enteric Neuroscience Translational and Epidemiological Research (C.E.N.T.E.R.), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, Minnesota, USA.ORCID 0000-0001-6472-7514

Funding

MULTIDISCRIPLINARY TRAINING IN DIGESTIVE DISEASEST32DK007198 · NIDDK · MAYO CLINIC ROCHESTER · PI Harmeet Malhi · 1986 to 2026
$8.9M
NIDDK NIH HHS T32 DK007198
6 · The paper itself

Abstract

introductionAltered intestinal permeability (IP) is implicated in multiple gastrointestinal and systemic disease conditions; an experimental model of perturbed IP in healthy subjects is needed. Traditional approaches to perturbing IP include use of nonsteroidal anti-inflammatory drugs.

methodsWe conducted a single-center, randomized, placebo-controlled pilot study of dose-related effects of castor oil (CO) (and its ingredient ricinoleic acid) at 750, 1,500, or 3,000 mg daily doses on IP. Permeability was assessed using validated 13 C-mannitol and lactulose urine excretion at 0-2, 8-24, and 0-24 hours after oral administration.

resultsPermeability analysis across all groups demonstrated significant difference among the groups for 0-2 hours 13 C-mannitol, 0-24 hours 13 C-mannitol, and borderline significant difference for 2-8 hours 13 C-mannitol ( P = 0.060) and 0-24 hours lactulose ( P = 0.056). Direct comparison of 3,000 mg CO vs placebo ( t test) demonstrated higher excretion of 13 C-mannitol and lactulose at 0-2, and 0-24 hours, and lactulose at 2-8 hours. DISCUSSION: CO may perturb small intestinal and colonic permeability in healthy adults.

Indexed as

Castor OilIntestinal AbsorptionIntestinal MucosaRicinoleic AcidsAdministration, OralAdultDose-Response Relationship, DrugDouble-Blind MethodFemaleHealthy VolunteersHumansLactuloseMaleMannitolMiddle AgedPermeabilityCastor OilLactuloseMannitolricinoleic acidRicinoleic Acidscastor oilintestinal permeabilityleaky gut

Identifiers

PMID40434309
PMCPMC12330349

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.